Exhibit 10.35 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the "Agreement") is made effective as of the 15th day of January, 2001 (the "Effective Date") by and between MICROCIDE PHARMACEUTICALS, INC.,...Collaborative Research and License Agreement • August 14th, 2001 • Microcide Pharmaceuticals Inc • Pharmaceutical preparations
AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between TARGACEPT, INC. and AVENTIS PHARMA SACollaborative Research and License Agreement • January 17th, 2006 • Targacept Inc • Pharmaceutical preparations • New York
This Amended and Restated Collaborative Research and License Agreement (this “Agreement”) is made and entered into as of January 21, 2002, by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (“Targacept”), and Aventis Pharma SA, a corporation organized and existing under the laws of France having its principal place of business at 20, avenue Raymond Aron, 92160 Antony, France (“APSA”) (each of Targacept and APSA a “Party” and collectively, the “Parties”).
1. DEFINITIONS -----------Collaborative Research and License Agreement • September 2nd, 1997 • Siga Pharmaceuticals Inc • Pharmaceutical preparations • New Jersey
EX-10.19 21 d386058dex1019.htm COLLABORATIVE RESEARCH AND LICENSE AGREEMENT Execution Copy COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between WARNER CHILCOTT COMPANY, INC. and PARATEK PHARMACEUTICALS, INC. July 2, 2007Collaborative Research and License Agreement • May 5th, 2020 • New York
Portions of this Exhibit, indicated by the mark “[***],” were omitted and have been filed separately with the Secretary of the Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 406 of the Securities Act of 1933, as amended.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT by and between TARGACEPT, INC. and ASTRAZENECA AB December 27, 2005Collaborative Research and License Agreement • May 26th, 2006 • Targacept Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 27, 2005 (the “Execution Date”), by and between Targacept, Inc., a Delaware corporation having an address of 200 East First Street, Suite 300, Winston-Salem, NC 27101-4165 (“Targacept”), and AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden, having its principal place of business at V-Malarehamnen 9, S-151 85 Södertälje, Sweden (“AstraZeneca”), effective as of the Effective Date, except for those provisions that are expressly stated to be effective as of the Execution Date, which shall be effective as of the Execution Date. Each of AstraZeneca and Targacept is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
EXHIBIT 10.18 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT This Collaborative Research and License Agreement is made and effective as of October 18, 1999 (the "Effective Date"), by and between 3-Dimensional Pharmaceuticals, Inc., a corporation having...Collaborative Research and License Agreement • July 28th, 2000 • 3 Dimensional Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and MERCK KGaA June 6, 2007Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 6, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Merck KGaA, a company organized under the laws of Germany with offices at Frankfurter Str. 250, 64293 Darmstadt, Germany (“MERCK”). Each of MERCK and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • June 9th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware Corporation having offices at 11099 North Torrey Pines Road, La Jolla, CA 92037 ("Senomyx") and KRAFT FOODS, INC., a Delaware Corporation having offices at 801 Waukegan Road, Glenview, IL 60025 ("Kraft").
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BY AND BETWEEN NOILE-IMMUNE BIOTECH, INC. AND LEGEND BIOTECH USA, INC. April 27, 2020Collaborative Research and License Agreement • May 29th, 2020 • Legend Biotech Corp • Pharmaceutical preparations
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is made as of April __, 2020 (the “Effective Date”) by and between Noile-Immune Biotech, Inc., a Japanese corporation having its principal place of business at 2-12-10 Shiba-Daimon, Minato-ku, Tokyo 105-0012, Japan (“Noile”), and Legend Biotech USA, Inc., a company incorporated under the laws of New York having its principal place of business at 10 Knightsbridge Road, Piscataway, NJ 08854, USA (“Legend”). Noile and Legend are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and TAKEDA PHARMACEUTICAL COMPANY LIMITED June 11, 2007Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 11, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Takeda Pharmaceutical Company Limited, a Japanese corporation with a principal place of business at 1-1, Doshomachi 4-chome, Chuo-ku, Osaka 540-8645, Japan (“TAKEDA”). Each of TAKEDA and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and ELAN PHARMA INTERNATIONAL, LIMITED June 30, 2006Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • Delaware
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of June 30, 2006, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Elan Pharma International Limited, a private company limited by shares organized under the laws of Ireland with offices at Monksland, Athlone, County Westmeath, Ireland (“ELAN”). Each of ELAN and ARCHEMIX is sometimes referred to individually herein as a “Party” and are sometimes referred to collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between TARGACEPT, INC. and AVENTIS PHARMA SACollaborative Research and License Agreement • January 17th, 2006 • Targacept Inc • Pharmaceutical preparations • Delaware
This Collaborative Research and License Agreement (this “Agreement”) is made and entered into as of January 21, 2002 (the “Effective Date”), by and between Targacept, Inc., a Delaware corporation having its principal place of business at 950 Reynolds Boulevard, Winston-Salem, North Carolina 27105 (“Targacept”), and Aventis Pharma SA, a corporation organized and existing under the laws of France having its principal place of business at 20, avenue Raymond Aron, 92160 Antony, France (“Aventis”). Each of Targacept and Aventis may be referred to individually herein as a “Party” and together as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between ARCHEMIX CORP. and MERCK, KGaA January 17, 2007Collaborative Research and License Agreement • December 19th, 2008 • Nitromed Inc • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of January 17, 2007, by and between Archemix Corp., a Delaware corporation with offices at 300 Third Street, Cambridge, MA 02142 (“ARCHEMIX”), and Merck KGaA, a company organized under the laws of Germany with offices at Frankfurter Str. 250, 64293 Darmstadt, Germany (“MERCK”). Each of MERCK and ARCHEMIX is sometimes referred to individually herein as a “Party” and collectively as the “Parties.”
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT BETWEEN BIOGEN MA INC. AND C4 THERAPEUTICS, INC. Dated December 28, 2018Collaborative Research and License Agreement • September 10th, 2020 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances) • New York
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of December 28, 2018 (the “Effective Date”) by and among Biogen MA Inc., a corporation organized and existing under the laws of Massachusetts and having a principal place of business at 225 Binney Street, Cambridge, MA 02142 (“Biogen”) and C4 Therapeutics, Inc., a corporation organized and existing under the laws of Delaware with a principle place of business at 490 Arsenal Way, Watertown, MA 02472 (“C4”). Biogen and C4 are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
RECITALSCollaborative Research and License Agreement • August 10th, 2001 • Isis Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • April 14th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
This Agreement is entered into as of the Effective Date by and between Senomyx, Inc., a Delaware Corporation having offices at 11099 North Torrey Pines Road, La Jolla, CA 92037 ("Senomyx") and NESTEC, Ltd., a Swiss company, having its principal place of business at Avenue Nestlé 55, CH-1800 Vevey, Switzerland ("Nestlé").
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT between Alexion Pharma Holding Unlimited Company Dicerna Pharmaceuticals Inc. and Dicerna Cayman DATED OCTOBER 22, 2018Collaborative Research and License Agreement • March 13th, 2019 • Dicerna Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (this “Agreement”) is entered into as of October 22, 2018 (the “Effective Date”) by and among ALEXION PHARMA HOLDING UNLIMITED COMPANY, an unlimited liability company incorporated under the laws of Ireland with a principal place of business at [***] (“ALEXION”), DICERNA PHARMACEUTICALS INC., a corporation organized and existing under the laws of Delaware with a principal place of business at 87 Cambridgepark Drive, Cambridge, MA 02140 (“DICERNA PHARMA”), and Dicerna Cayman, an exempted company incorporated with limited liability under the laws of the Cayman Islands (“DICERNA CAYMAN”, and together with DICERNA PHARMA, “DICERNA”). ALEXION and DICERNA are sometimes referred to herein individually as a “Party” and collectively as the “Parties”.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • May 17th, 1999 • Aurora Biosciences Corp • Services-commercial physical & biological research • Aurora
CERTAIN CONFIDENTIAL MATERIAL APPEARING IN THIS DOCUMENT, MARKED BY [********], HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 24B-2 PROMULGATED UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED....Collaborative Research and License Agreement • March 14th, 2014 • Targacept Inc • Pharmaceutical preparations
This Amendment No. 6 to Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the Collaborative Research and License Agreement entered into as of December 27, 2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”), as amended by Amendment No. 1 dated November 10, 2006, Amendment No. 2 effective July 8, 2009, Amendment No. 3 effective April 30, 2010, Amendment No. 4 effective September 28, 2010 and Amendment No. 5 effective March 5, 2013 (the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement.
ContractCollaborative Research and License Agreement • May 5th, 2020 • New York
<DOCUMENT> <TYPE>EX-10.7 <SEQUENCE>16 <FILENAME>a2025040zex-10_7.txt <DESCRIPTION>EX 10.7 <TEXT> <PAGE> EXHIBIT 10.7 COLLABORATIVE RESEARCH AND LICENSE AGREEMENT THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("the Agreement") is entered into as of January 31, 1999 ("Effective Date") by and between PFIZER INC, a Delaware corporation, having an office at 235 East 42nd Street, New York, New York 10017-5755 ("Pfizer") and RIGEL PHARMACEUTICALS, INC., a Delaware corporation, having an address at 772 Lucerne Drive, Sunnyvale, California 94086 ("Rigel"). Pfizer and Rigel and their Affiliates may be referred to herein individually as a "Party" or collectively as the "Parties." WHEREAS, Rigel has the capability and expertise to undertake research for the discovery of novel and selective elements of the IL-4 signaling pathway involved in the modulation of IgE synthesis that are suitable targets for an IgE synthesis-inhibitor, lead identification program; WHEREAS, Rigel owns the patents, pate
EX-10.13 2 d273854dex1013.htm AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT CONFIDENTIAL TREATMENT REQUESTED Final Execution Version AMENDED AND RESTATED COLLABORATIVE RESEARCH AND LICENSE AGREEMENT By and Among pSivida Corp....Collaborative Research and License Agreement • May 5th, 2020 • New York
This Amended and Restated Collaborative Research and License Agreement (the “Agreement”), dated as of June 14, 2011 (the “Effective Date”), is made by and among pSivida Corp., a Delaware corporation with offices located at 400 Pleasant Street, Watertown, Massachusetts, 02472, pSivida US, Inc., a Delaware corporation with offices located at 400 Pleasant Street, Watertown, Massachusetts 02472, pSiMedica Limited, a United Kingdom limited company with offices located at Malvern Hills Science Park, Geraldine Road, Malvern, Worcestershire, WR14 3SZ (collectively, “PSIVIDA”) and Pfizer Inc., a Delaware corporation with offices located at 235 East 42nd Street, New York, New York, 10017 (“PFIZER”). PSIVIDA and PFIZER are sometimes referred to herein individually as a “Party” and collectively as the “Parties.”
FOURTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • August 7th, 2008 • Senomyx Inc • Services-commercial physical & biological research • California
THIS FOURTH AMENDMENT TO THE COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Fourth Amendment”) is entered into as of April 14, 2008 (“Fourth Amendment Effective Date”) by and between SENOMYX, INC. (“Senomyx”), a Delaware corporation, having a principal place of business at 4767 Nexus Centre Drive, San Diego, CA 92121, and NESTEC, Ltd. (“Nestlé”), a Swiss company, having a principal place of business at Avenue Nestlé 55, CH-1800 Vevey, Switzerland.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT The Dow Chemical Company - Symyx TechnologiesCollaborative Research and License Agreement • March 15th, 2011 • Accelrys, Inc. • Services-prepackaged software • Delaware
This COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Agreement”), effective as of January 1, 1999 (the “Effective Date”), is made by and between Symyx Technologies, a California corporation having a principal place of business at 3100 Central Expressway, Santa Clara, California 95051 (“Symyx”), and The Dow Chemical Company, a Delaware corporation, having a principal place of business at 2030 Willard H. Dow Center, Midland, Michigan 48674 (“TDCC”).
Certain information in this document has been omitted from this exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • March 11th, 2021 • C4 Therapeutics, Inc. • Biological products, (no disgnostic substances)
THIS AMENDMENT NO. 1 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENT ("Amendment") is made as of February 25, 2020, by and among C4 Therapeutics, Inc., a Delaware corporation ("C4") and Biogen MA Inc., a Massachusetts corporation ("Biogen").
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission. COLLABORATIVE RESEARCH AND LICENSE AGREEMENT Between INCYTE CORPORATION and PFIZER INC. Dated as of...Collaborative Research and License Agreement • March 3rd, 2006 • Incyte Corp • Services-commercial physical & biological research • New York
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Agreement”) is entered into as of November 18, 2005 by and between INCYTE CORPORATION, a Delaware corporation with its offices at Experimental Station, Route 141 and Henry Clay Road, Building E336, Wilmington, DE 19880 (“Incyte”), and PFIZER INC., a Delaware corporation with its offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”). Incyte and Pfizer may be referred to herein individually as a “Party” or collectively, as the “Parties”.
INDICATES CONFIDENTIAL MATERIAL OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL TREATMENT AND FILED WITH THE SECURITIES AND EXCHANGE COMMISSION SEPARATELY WITH A REQUEST FOR CONFIDENTIAL TREATMENT. COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • July 27th, 2015 • Benitec Biopharma LTD/ADR • Pharmaceutical preparations • New York
This COLLABORATIVE RESEARCH and LICENSE AGREEMENT (this “Agreement”) is entered into as of November 11, 2014 (the “Effective Date”) between Benitec Biopharma Limited, an Australian company (“Benitec”), and 4D Molecular Therapeutics, LLC, a Delaware limited liability company (“4D Molecular” or “4D”). Each of Benitec and 4D Molecular shall be a “Party” or collectively, the “Parties.”
AMENDMENT NO. 4 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • November 5th, 2010 • Targacept Inc • Pharmaceutical preparations
This Amendment No. 4 to Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the Collaborative Research and License Agreement entered into as of December 27, 2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”), as amended by Amendment No. 1 dated November 10, 2006, Amendment No. 2 effective July 8, 2009, and Amendment No. 3 effective April 30, 2010 (the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement.
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • May 6th, 2005 • Rigel Pharmaceuticals Inc • Pharmaceutical preparations • Delaware
THIS COLLABORATIVE RESEARCH AND LICENSE AGREEMENT (the “Agreement”) is entered into as of January 18, 2005 by and between RIGEL PHARMACEUTICALS, INC., a Delaware corporation with its offices at 1180 Veterans Boulevard, South San Francisco, California 94080 (“Rigel”), and PFIZER INC., a Delaware corporation with its offices at 235 East 42nd Street, New York, New York 10017 (“Pfizer”). Rigel and Pfizer may be referred to herein individually as a “Party” or collectively, as the “Parties.”
1 EXHIBIT 10.27 COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • November 14th, 1997 • Aurora Biosciences Corp • Services-commercial physical & biological research • California
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • June 9th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
This Agreement is entered into as of the Effective Date by and between Senomyx, Inc., a Delaware Corporation having offices at 11099 North Torrey Pines Road, La Jolla, CA 92037 ("Senomyx") and Campbell Soup Company, having its principal place of business at Campbell Place, Camden, NJ 08103-1799 ("Campbell").
COLLABORATIVE RESEARCH AND LICENSE AGREEMENT by and between IMMUNOGEN, INC.Collaborative Research and License Agreement • May 15th, 2001 • Immunogen Inc • Pharmaceutical preparations • California
AMENDMENT NO. 2 TO COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • November 6th, 2009 • Targacept Inc • Pharmaceutical preparations
This Amendment No. 2 to Collaborative Research and License Agreement (this “Amendment”), effective as of the date of signature of the last Party to sign below, amends the Collaborative Research and License Agreement entered into as of December 27, 2005 by and between AstraZeneca AB, a company limited by shares organized and existing under the laws of Sweden (“AstraZeneca”), and Targacept, Inc., a Delaware (USA) corporation (“Targacept”), as amended by Amendment No. 1 dated November 10, 2006 (the “Agreement”). Capitalized terms used herein and not otherwise defined shall have the meanings ascribed to them in the Agreement.
RECITALSCollaborative Research and License Agreement • March 31st, 1998 • Axys Pharmecueticals Inc • Pharmaceutical preparations • New York
AMENDMENTCollaborative Research and License Agreement • March 31st, 2003 • Isis Pharmaceuticals Inc • Pharmaceutical preparations
This Amendment to the Collaborative Research and License Agreement dated July 9, 2001, ("Agreement"), by and between ISIS PHARMACEUTICALS, INC. ("Isis"), a Delaware corporation, with its principal office at 2292 Faraday Avenue, Carlsbad, California 92008 and PE CORPORATION (NY), a New York corporation, through the CELERA GENOMICS GROUP, ("Celera"), having a principal place of business at 45 West Gude Drive, Rockville, Maryland 20850. Celera and Isis may be referred to herein individually as a "Party" and collectively as the "Parties".
COLLABORATIVE RESEARCH AND LICENSE AGREEMENTCollaborative Research and License Agreement • April 14th, 2004 • Senomyx Inc • Services-commercial physical & biological research • California
THIS AGREEMENT is entered into as of the Effective Date by and between SENOMYX, INC., a Delaware corporation having offices at 11099 North Torrey Pines Road, La Jolla, California 92037 ("Senomyx"), and AURORA BIOSCIENCES CORPORATION, a Delaware corporation having offices at 11010 Torreyana Road, San Diego, California 92121 ("Aurora").
